Abstract:This paper takes biological drug thrombomodulin α which listed by Japan's Asahi Kasei Pharmaceutical Company in 2008 as an example to reflex the innovative drug's policy environment in Japan by studying the lifecycle of the drug.The empirical study of the product from research and development,registration and all the aspects after listing can help us analyze the Japanese government policy supported deeply in all aspects.Therefore,we can make relevant recommendations to complete the policy environment of innovative drugs in China.

Research on policy environment of Japanese innovative drug——an empirical analysis based on thrombomodulin α